← Back to Search

Balance Training for Multiple Sclerosis

N/A
Waitlist Available
Research Sponsored by Wayne State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Stable medication regime for 3 months prior to enrollment
Able to follow study-related commands
Must not have
History of hospitalization for depression
Depression as evidenced by a score of ≥10 on the Patient Health Questionnaire-9 (PHQ-9)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up outcome will be assessed at baseline visit and post-test visit (1 week later)
Awards & highlights
No Placebo-Only Group

Summary

This trial is designed to study how well people with MS can learn new motor skills, and what factors might help predict successful learning.

Who is the study for?
This trial is for individuals aged 18-65 with Relapsing-Remitting Multiple Sclerosis who can walk with or without help. They must have been on a stable medication regime for the past 3 months and be able to follow study instructions. People are excluded if they have other neurological conditions, recent steroid use, metal implants incompatible with MRI, current pregnancy, or significant depression.
What is being tested?
The study investigates how people with MS relearn motor skills through balance training. It aims to identify clinical and brain-related factors that predict successful learning of these skills. Participants will undergo cognitive tests, neuroimaging, and train on a balance task over four days followed by post-testing after two days.
What are the potential side effects?
Since this trial focuses on balance training rather than drug intervention, typical side effects associated with medications are not expected. However, participants may experience fatigue or physical discomfort from the exercises involved in the motor skill learning process.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My medications have not changed in the last 3 months.
Select...
I can understand and follow study instructions.
Select...
I can walk with or without help.
Select...
I am between 18 and 65 years old.
Select...
I have been diagnosed with Relapsing-Remitting MS.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been hospitalized for depression before.
Select...
I have depression with a score of 10 or higher on the PHQ-9.
Select...
I have a history of neurological or muscle-related conditions.
Select...
I have a recent bone or joint problem that stops me from training.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~outcome will be assessed at baseline visit and post-test visit (1 week later)
This trial's timeline: 3 weeks for screening, Varies for treatment, and outcome will be assessed at baseline visit and post-test visit (1 week later) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Dual-Task Cost
Secondary study objectives
Berg Balance Scale
Objective Balance Control

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ExperimentalExperimental Treatment1 Intervention
Balance Training
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Balance Training
2018
N/A
~960

Find a Location

Who is running the clinical trial?

Wayne State UniversityLead Sponsor
314 Previous Clinical Trials
109,938 Total Patients Enrolled
7 Trials studying Multiple Sclerosis
629 Patients Enrolled for Multiple Sclerosis

Media Library

Balance Training Clinical Trial Eligibility Overview. Trial Name: NCT03404388 — N/A
Multiple Sclerosis Research Study Groups: Experimental
Multiple Sclerosis Clinical Trial 2023: Balance Training Highlights & Side Effects. Trial Name: NCT03404388 — N/A
Balance Training 2023 Treatment Timeline for Medical Study. Trial Name: NCT03404388 — N/A
~5 spots leftby Jan 2025